6857-88-1

Basic information

• Product Name: [3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid
• Synonyms: (3aS,5aS,6R,9aR,9bS)-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid;[3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid;4-Nor-3,5-seco-5,17-dioxoandrostan-3-oic Acid;5,17-Dioxo-3,5-seco-A-norandrostan-3-oic Acid
• CAS NO: 6857-88-1
• Molecular Formula: C₁₈H₂₆O₄
• Molecular Weight: 306.39664
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 6857-88-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: [3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid(6857-88-1)
• EPA Substance Registry System: [3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid(6857-88-1)

Safety Data

• Hazardous Substances Data: 6857-88-1(Hazardous Substances Data)

Usage

Chemical Properties

White to Off-White Solid

Uses

4-Nor-3,5-seco-5,17-dioxoandrostan-3-oic Acid is an open A-ring steroid. It is used in the preparation on heterocyclic steroids such as Finesteride.

Upstream product

• 63-05-8 Androstenedione 
• 67-64-1 acetone 

Downstream Products

• 1315357-75-5 C₂₉H₄₂O₇S 
• 51478-09-2 4-aza-5α-androstene-3,17-dione 
• 98319-24-5 dihydro-finasteride 
• 98319-26-7 finasteride 

Relevant articles and documents

Photochemical reactions. 21. Sensitized photooxygenation of N-methylated 4-aza-5-androsten-3-one and 4-aza-5-androstene steroidal systems

-

Shielding effect of ether C-O bond obtained from proton chemical shifts of 4-oxa-5α- and 4-oxa-5β-androstan-17-ones

4-Oxa-5α- and 4-oxa-5β-androstanones (1 and 2) were synthesized in order to obtained the NMR shielding parameters for the ether C-O bond. The complete NMR assignment of both the proton and carbon atoms for these compounds and substituent-induced shifts (SIS) from the corresponding androstanones (3 and 4) are presented. The comparison of the molecular structure obtained by MM3 calculation with that of X-ray crystallographic analysis disclosed that the former structure is completly superimposable to the latter in both of the compounds 1 and 2. A combination of the electric field effect and the anisotropy of the magnetic susceptibility of the C-O bond can successfully reproduce the observed SIS values for these androstanones.

CYP11B, CYP17, AND/OR CYP21 INHIBITORS

Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions. Formula (Z)

DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS

Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.